Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 1 |
| Contraceptives Market to 2018 - Introduction | 10 | 2 |
| Contraceptives Market to 2018 - Market Overview | 12 | 7 |
| Introduction | 12 | 1 |
| Revenue Forecasts for Contraceptives Market | 12 | 1 |
| Revenues | 12 | 1 |
| Global Contraceptives Revenue Share by Geography | 13 | 2 |
| Annual Cost of Usage for Contraceptives | 15 | 1 |
| Contraceptive Users | 16 | 1 |
| Drivers and Barriers for the Contraceptives Market | 17 | 1 |
| Drivers for Contraceptives Therapeutics Market | 17 | 1 |
| Regulatory changes will improve the Usage Pattern | 17 | 1 |
| Increase in Awareness about the Use of Contraceptives | 17 | 1 |
| Launch of Novel Contraceptives in the Forecast Period | 17 | 1 |
| Barriers for Contraceptives | 18 | 1 |
| Side Effects of Contraceptives | 18 | 1 |
| Patent Expiry of Contraceptives Such as Yaz and Mirena | 18 | 1 |
| Contraceptives Market to 2018 - Geographical Landscape | 19 | 9 |
| The US | 19 | 1 |
| Revenue | 19 | 1 |
| Annual Cost of Usage for Contraceptives | 20 | 1 |
| Contraceptive Users | 21 | 1 |
| Top Five Countries of Europe | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Usage for Contraceptives | 23 | 1 |
| Contraceptive Users | 24 | 1 |
| Japan | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Usage for Contraceptives | 26 | 1 |
| Contraceptive Users | 27 | 1 |
| Contraceptives Market to 2018 - Therapeutic Landscape | 28 | 19 |
| Oral Contraceptives | 28 | 1 |
| Introduction | 28 | 1 |
| 21-Day Combined Oral Contraceptives | 28 | 1 |
| 4-phasic Regimen | 28 | 1 |
| 24-day Combined Oral Contraceptives | 28 | 1 |
| Extended cycle combined oral contraceptives | 28 | 1 |
| Continuous-Cycle Combined Oral Contraceptive | 28 | 1 |
| Combined Hormonal Contraception | 29 | 1 |
| Oral Contraceptive Historic Trends | 29 | 1 |
| Recently Approved Combined Oral Contraceptives | 29 | 1 |
| Revenue | 30 | 1 |
| Geographical Segmentation | 31 | 2 |
| Annual Cost of Usage | 33 | 1 |
| Oral Contraceptive Users | 34 | 1 |
| Injectables | 35 | 1 |
| Introduction | 35 | 1 |
| Revenue | 35 | 2 |
| Geographical Segmentation | 37 | 2 |
| Annual Cost of Usage | 39 | 1 |
| Injectable Contraceptive Users | 40 | 1 |
| Topical Contraceptives | 41 | 1 |
| Introduction | 41 | 1 |
| Revenue | 42 | 1 |
| Geographical Segmentation | 43 | 2 |
| Annual Cost of Usage | 45 | 1 |
| Topical Contraceptive Users | 46 | 1 |
| Contraceptives Market to 2018 - Devices Landscape | 47 | 17 |
| Vaginal Ring | 47 | 1 |
| Introduction | 47 | 1 |
| Revenue | 47 | 2 |
| Geographical Segmentation | 49 | 2 |
| Annual Cost of Usage | 51 | 1 |
| Vaginal Ring Users | 52 | 1 |
| Intrauterine Device | 53 | 1 |
| Introduction | 53 | 1 |
| Revenue | 53 | 2 |
| Geographical Segmentation | 55 | 2 |
| Annual Cost of Usage | 57 | 1 |
| IUDs Users | 58 | 1 |
| Condoms | 59 | 1 |
| Introduction | 59 | 1 |
| Revenue | 59 | 1 |
| Geographical Segmentation | 60 | 2 |
| Annual Cost of Usage | 62 | 1 |
| Condom Users | 63 | 1 |
| Emerging Markets | 64 | 3 |
| China | 64 | 1 |
| Australia | 65 | 1 |
| India | 66 | 1 |
| Contraceptives Market to 2018 - Pipeline Analysis | 67 | 3 |
| Introduction | 67 | 1 |
| Profiles of Promising Drugs in the Global Contraceptives Market | 68 | 1 |
| AG200-15 | 68 | 1 |
| Overview | 68 | 1 |
| Efficacy | 68 | 1 |
| Safety | 68 | 1 |
| Clinical Study Details | 68 | 1 |
| FC Patch Low | 68 | 1 |
| Overview | 68 | 1 |
| Efficacy | 69 | 1 |
| Safety | 69 | 1 |
| Clinical Study Details | 69 | 1 |
| Pill-Plus | 69 | 1 |
| Overview | 69 | 1 |
| Efficacy | 69 | 1 |
| Safety | 69 | 1 |
| Clinical Study Details | 69 | 1 |
| Contraceptives Market to 2018 - Competitive Landscape | 70 | 7 |
| Market Share Analysis - Contraceptives Market | 70 | 1 |
| Drug Profile of Major Marketed Contraceptives | 71 | 1 |
| Yaz/Yasmin | 71 | 1 |
| Overview | 71 | 1 |
| Mirena | 71 | 1 |
| Overview | 71 | 1 |
| Nuvaring | 71 | 1 |
| Overview | 71 | 1 |
| Competitive Profiling | 72 | 1 |
| Bayer | 72 | 1 |
| Overview | 72 | 1 |
| SWOT Analysis | 72 | 1 |
| Merck | 73 | 1 |
| Overview | 73 | 1 |
| SWOT Analysis | 73 | 1 |
| Church &Dwight | 74 | 1 |
| Overview | 74 | 1 |
| SWOT Analysis | 74 | 1 |
| Warner Chilcott Company, Inc. | 75 | 1 |
| Overview | 75 | 1 |
| SWOT Analysis | 75 | 1 |
| Pfizer Inc. | 76 | 1 |
| Overview | 76 | 1 |
| SWOT Analysis | 76 | 1 |
| Contraceptives Market to 2018 - Strategic Consolidations | 77 | 3 |
| Mergers and Acquisitions | 77 | 1 |
| Major M&A Deals | 77 | 1 |
| BioSante Pharma Merges with Cell Genesys | 77 | 1 |
| Bayer Acquires Minority Stake in Bayer Schering Pharma | 77 | 1 |
| Licensing Agreements | 77 | 1 |
| Deals by Geography | 78 | 1 |
| Major Licensing Agreements | 78 | 1 |
| ASKA Pharma Enters into Licensing Agreement With HRA Pharma For ellaOne | 78 | 1 |
| Warner Chilcott Enters into Licensing Agreement with Lupin for Femcon Fe | 78 | 1 |
| HRA Pharma Expands Licensing Agreement with Watson Pharma for Ulipristal | 78 | 1 |
| Watson Pharma Enters into Licensing Agreement with Teva Pharma | 79 | 1 |
| Watson Pharma Enters into Licensing Agreement with Population Council | 79 | 1 |
| HRA Pharma Enters into Licensing Agreement with Hyphens | 79 | 1 |
| Co-development | 79 | 1 |
| Contraceptives Market to 2018 - Appendix | 80 | 6 |
| Market Definitions | 80 | 1 |
| Abbreviations | 80 | 1 |
| Bibliography | 80 | 1 |
| Research Methodology | 81 | 3 |
| Coverage | 82 | 1 |
| Secondary Research | 82 | 1 |
| Primary Research | 82 | 1 |
| Expert Panel Validation | 83 | 1 |
| Therapeutic Landscape | 83 | 2 |
| Epidemiology-Based Forecasting | 83 | 1 |
| Market Size by Geography | 84 | 1 |
| Geographical Landscape | 84 | 1 |
| Pipeline Analysis | 84 | 1 |
| Competitive Landscape | 84 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 85 | 1 |